Sam Dagogo-Jack, MD, DSc, is Professor of Medicine and Chief of the Division of Endocrinology, Diabetes, and Metabolism at the University of Tennessee Health Science Center (UTHSC) in Memphis, where he holds the A.C. Mullins Endowed Professorial Chair in Translational Research. He is also Director of the General Clinical Research Center at UTHSC. Dr. Dagogo-Jack’s current research focuses on the interaction of genetic and environmental factors in the pathobiology of prediabetes and prevention of diabetes. He is a past president, Medicine and Science, of the American Diabetes Association and a recipient of the Banting Medal for Leadership from the American Diabetes Association and the Distinction in Endocrinology Award from the American College of Endocrinology.
Disclosures
-
Published:2021
2021. "Disclosures", Prediabetes: A Fundamental text. Pathophysiology, Complications, Management, Reversal, Sam Dagogo-Jack, MD, DSc
Download citation file:
Dr. Dagogo-Jack has served as a principal investigator or co-investigator for clinical trial contracts between the University of Tennessee and AstraZeneca, Novo Nordisk, and Boehringer-Ingelheim; has served as a consultant and advisory board member for AstraZeneca, Bayer, Boehringer-Ingelheim, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi; and holds equity interests in Jana Care, Inc., and Aerami Therapeutics. He has also served as an expert for Sidley Austin, Adam and Reese, and Wheeler Trigg O’Donnell law firms on litigation related to diabetes and hormonal disorders.